Eleven Biotherapeutics. All rights reserved. 2017 Eleven Biotherapeutics. All rights reserved. Targeting Cancer with POWER+PRECISION 2017 Eleven Biotherapeutics. All rights reserved. This presentation contains forward-lo
Friday, October 20, 2017 1 min read
Key Takeaway: An Open-Label, Multicenter, Phase 3 Study to Evaluate the Efficacy and Tolerability of Intravesical ViciniumTM in Subjects with Non Muscle Invasive Carcinoma in Situ (CIS) and/or High-Grade Papillary Disease of the Bladder Previously Treated with Bacillus Calmette Gu rin (BCG) ht
Full Press Release Details
An Open-Label, Multicenter, Phase 3 Study to Evaluate the Efficacy and Tolerability of Intravesical ViciniumTM in Subjects with Non Muscle Invasive Carcinoma in Situ (CIS) and/or High-Grade Papillary Disease of the Bladder Previously Treated with Bacillus Calmette Gu rin (BCG) https://clinicaltrials.gov/ct2/show/NCT02449239